Journal: Breast Cancer (Tokyo, Japan)
Article Title: IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses
doi: 10.1007/s12282-025-01687-6
Figure Lengend Snippet: Overview of IRSN-23 pCR-prediction without anti-HER2 therapy in breast cancer. A Meta-analysis of all datasets. The gray-shaded areas show the results of the present study. B Pooled analysis of each subtype and treatment. C IRSN-23 immune scores (IS) and pCR rates for each subtype. The solid lines and bands represent loess regression fitting (span = 2), and 95% confidence intervals were implemented using the R function geom_smooth. Abbreviations in the figure are as follows: GPL570 Affymetrix Human Genome U133 Plus 2.0 Array, GPL571 Affymetrix Human Genome U133A 2.0 Array, GPL96 Affymetrix Human Genome U133A Array, GPL6884 Illumina HumanWG-6 v3.0 expression beadchip, GPL1352 Affymetrix Human X3P, GPL6480 Agilent-014850 Whole Human Genome Microarray 4 × 44 K G4112F, A anthracycline, T taxane, Pac paclitaxel, Doc docetaxel, Ixa ixabepilone. Predictors of chemotherapy sensitivity and clinical utility
Article Snippet: Gene expression analysis was performed using Affymetrix U133A Plus 2.0 DNA microarray since the last publication.
Techniques: Expressing, Microarray